戻る Agenda
Session 1 : Regulatory science perspective on Drug development using innovative tool
Session Chair(s)
Younglim Kim, PhD
Director General
National Institute of Food & Drug Safety (NIFDS), Korea, Republic of
Kyung Won Seo
Director General, National Institute of Food and Drug Safety Evaluation
Ministiry of Food and Drug Safety, Korea, Republic of
Speaker(s)
Meghana Chalasani, MHA
FDA, United States
Associate Director for Clinical Trial Innovation, Office of New Drugs, CDER
Session 1 - 2
Susan M Sandler, RPh
Johnson & Johnson, United Kingdom
Director, Global Regulatory Policy and Intelligence
Session 1 - 3
Hironobu Saito, PhD
Tottori University, Chromosome Egineering Research Center, Japan
Specially Appointed Professor
Session 1 - 4
Sohee Kim
Korean Ministry of Food and Drug Safty (MFDS), Korea, Republic of
Division Director
Session 1 - 5
Junhee Pyo
KPBMA, Korea, Republic of
Vice Chief, Convergence AI Institute for Drug Discovery
HaeSun Suh, PhD
Kyung Hee University, Korea, Republic of
Professor, College of Pharmacy
Minseok Kim
JNPMEDI, Korea, Republic of
CBO